As of 2024, the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for several drugs, offering extended market protection. These grants are typically awarded for conducting studies in pediatric populations.
What is Pediatric Exclusivity?
Pediatric exclusivity is a form of market protection granted by the FDA that extends the patent protection of a drug for six months. This incentive is provided when drug manufacturers conduct studies in pediatric populations as part of their development program. The goal is to encourage research and the availability of safe and effective treatments for children [1].
How Does a Drug Qualify for Pediatric Exclusivity?
A drug qualifies for pediatric exclusivity if the FDA requests pediatric studies for the drug and the sponsor agrees to conduct them [1]. These studies must be completed, and the results submitted to and approved by the FDA. The exclusivity period starts from the date of approval of the pediatric studies and lasts for six months. This is separate from any existing patent protection [2].
Which Drugs Have Received Pediatric Exclusivity?
The FDA does not maintain a publicly accessible, real-time list of all drugs granted pediatric exclusivity. However, information on such grants is often disclosed in regulatory filings and can be tracked through patent databases and drug approval documents. For a comprehensive and up-to-date view, resources that track drug patents and exclusivity periods are essential. DrugPatentWatch.com is a valuable source for this type of information, detailing patent expirations and various exclusivity periods, including pediatric exclusivity [3].
When Does Pediatric Exclusivity Typically Expire?
Pediatric exclusivity adds six months to the existing market exclusivity of a drug. This extension begins after the expiration of other forms of exclusivity, such as new chemical entity (NCE) exclusivity or patent expiry, unless the pediatric studies are approved before these expirations. In such cases, the six-month exclusivity period may commence after the existing exclusivity ends [2].
Can Companies Challenge Pediatric Exclusivity?
While pediatric exclusivity is granted by the FDA based on conducted studies, the broader patent landscape for a drug can be subject to legal challenges. Companies, particularly generic or biosimilar manufacturers, may challenge patents that are core to a drug's market protection. These challenges can influence the ultimate timeline for market entry for alternative versions of a drug [4].
What are the Implications for Generic and Biosimilar Drugs?
The grant of pediatric exclusivity can delay the entry of generic or biosimilar versions of a drug. By extending the period of market protection for the innovator drug, it effectively pushes back the date when lower-cost alternatives can become available to patients and healthcare systems [2][4].
Where Can I Find More Detailed Information on Drug Exclusivity?
For detailed information on specific drugs, patent statuses, and various forms of market exclusivity, including pediatric exclusivity, consulting specialized databases is recommended. DrugPatentWatch.com provides extensive data on drug patents and exclusivity, offering insights into intellectual property rights and market dynamics [3].
---
Sources:
[1] U.S. Food & Drug Administration. "Orphan Drug Act." https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/orphan-drug-act
[2] U.S. Food & Drug Administration. "Drug Exclusivity Basics." https://www.fda.gov/drugs/patent-literacy/drug-exclusivity-basics
[3] DrugPatentWatch.com. https://drugpatentwatch.com/
[4] U.S. Food & Drug Administration. "FDA and Generic Drugs." https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/generic-drugs/fda-and-generic-drugs